share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  05/09 08:02
Moomoo AI 已提取核心信息
On May 7, 2024, 180 Life Sciences Corp. experienced significant leadership changes, as detailed in a Form 8-K report filed with the SEC. Dr. James N. Woody resigned as CEO and from the Board of Directors, entering into a separation agreement that includes a severance package and potential future contingent payment. Dr. Jonathan Rothbard also resigned as Chief Scientific Officer, with a modest cash settlement and a subsequent consulting agreement. Dr. Lawrence Steinman stepped down as Executive Chairman but remains on the Board and was appointed to the Strategy and Alternatives Committee. Blair Jordan was appointed as Interim CEO and entered into an Executive Consulting Agreement with the company. The Board of Directors set new compensation rates for non-executive Board members and entered into indemnity agreements with its directors and officers, excluding the CFO who already had such an agreement. These leadership transitions and contractual agreements are part of the company's ongoing governance and management adjustments.
On May 7, 2024, 180 Life Sciences Corp. experienced significant leadership changes, as detailed in a Form 8-K report filed with the SEC. Dr. James N. Woody resigned as CEO and from the Board of Directors, entering into a separation agreement that includes a severance package and potential future contingent payment. Dr. Jonathan Rothbard also resigned as Chief Scientific Officer, with a modest cash settlement and a subsequent consulting agreement. Dr. Lawrence Steinman stepped down as Executive Chairman but remains on the Board and was appointed to the Strategy and Alternatives Committee. Blair Jordan was appointed as Interim CEO and entered into an Executive Consulting Agreement with the company. The Board of Directors set new compensation rates for non-executive Board members and entered into indemnity agreements with its directors and officers, excluding the CFO who already had such an agreement. These leadership transitions and contractual agreements are part of the company's ongoing governance and management adjustments.
2024年5月7日,180生命科学公司经历了重大的领导层变动,向美国证券交易委员会提交的8-K表格报告中详述了这一点。James N. Woody博士辞去了首席执行官和董事会的职务,签订了离职协议,其中包括遣散费和未来可能的或有付款。乔纳森·罗斯巴德博士也辞去了首席科学官的职务,达成了适度的现金结算,随后签订了咨询协议。劳伦斯·斯坦曼博士辞去了执行主席的职务,但仍在董事会任职,并被任命为战略与替代委员会成员。布莱尔·乔丹被任命为临时首席执行官,并与该公司签订了执行咨询协议。董事会为非执行董事会成员设定了新的薪酬标准,并与其董事和高级管理人员签订了赔偿协议,但已签订此类协议的首席财务官除外。这些领导层过渡和合同协议是公司正在进行的治理和管理调整的一部分。
2024年5月7日,180生命科学公司经历了重大的领导层变动,向美国证券交易委员会提交的8-K表格报告中详述了这一点。James N. Woody博士辞去了首席执行官和董事会的职务,签订了离职协议,其中包括遣散费和未来可能的或有付款。乔纳森·罗斯巴德博士也辞去了首席科学官的职务,达成了适度的现金结算,随后签订了咨询协议。劳伦斯·斯坦曼博士辞去了执行主席的职务,但仍在董事会任职,并被任命为战略与替代委员会成员。布莱尔·乔丹被任命为临时首席执行官,并与该公司签订了执行咨询协议。董事会为非执行董事会成员设定了新的薪酬标准,并与其董事和高级管理人员签订了赔偿协议,但已签订此类协议的首席财务官除外。这些领导层过渡和合同协议是公司正在进行的治理和管理调整的一部分。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息